Dong-A ST Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 04:26 am EDT
Share
Dong-A ST Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 2,315.33 million compared to KRW 2,708.68 million a year ago. Net income was KRW 1,825.16 million compared to KRW 3,018.6 million a year ago. Basic loss per share from continuing operations was KRW 65.6863 compared to basic earnings per share from continuing operations of KRW 728.4314 a year ago. Basic loss per share was KRW 65.6863 compared to basic earnings per share of KRW 728.4314 a year ago.
For the six months, sales was KRW 4,791.68 million compared to KRW 5,280.14 million a year ago. Net income was KRW 9,517.86 million compared to KRW 4,756.28 million a year ago. Basic earnings per share from continuing operations was KRW 675.4902 compared to KRW 816.6667 a year ago. Basic earnings per share was KRW 675.4902 compared to KRW 816.6667 a year ago.
Dong-A ST Co Ltd is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company is involved of the manufacturing and sale of gastric mucosal protective agents, antihistamines, ischemic modifiers, antithrombotic agents, functional dyspepsia, hyperlipidemia, growth hormone, peptic ulcer treatments, cerebral metabolism improvement and hypertension treatments. It produces and sells diagnostic reagents for hepatitis E, I, A and B. In addition, it is engaged in the production and sale of medical devices including implants for artificial joint and maxillofacial surgery. The Company distributes its products in domestic and overseas markets such as Brazil, Turkey and Cambodia.
DONG-A ST CO., LTD. 
